PMID- 36157456 OWN - NLM STAT- MEDLINE DCOM- 20220928 LR - 20220928 IS - 1664-2392 (Print) IS - 1664-2392 (Electronic) IS - 1664-2392 (Linking) VI - 13 DP - 2022 TI - Fasting and stimulated glucagon-like peptide-1 exhibit a compensatory adaptive response in diabetes and pre-diabetes states: A multi-ethnic comparative study. PG - 961432 LID - 10.3389/fendo.2022.961432 [doi] LID - 961432 AB - BACKGROUND: Impaired secretion of glucagon-like peptide-1 (GLP-1) among Caucasians contributes to reduced incretin effect in type 2 diabetes mellitus (T2DM) patients. However, studies emanating from East Asia suggested preserved GLP-1 levels in pre-diabetes (pre-DM) and T2DM. We aimed to resolve these conflicting findings by investigating GLP-1 levels during oral glucose tolerance test (OGTT) among Malay, Chinese, and Indian ethnicities with normal glucose tolerance (NGT), pre-DM, and T2DM. The association between total GLP-1 levels, insulin resistance, and insulin sensitivity, and GLP-1 predictors were also analyzed. METHODS: A total of 174 subjects were divided into NGT (n=58), pre-DM (n=54), and T2DM (n=62). Plasma total GLP-1 concentrations were measured at 0, 30, and 120 min during a 75-g OGTT. Homeostasis model assessment of insulin resistance (HOMA-IR), HOMA of insulin sensitivity (HOMA-IS), and triglyceride-glucose index (TyG) were calculated. RESULTS: Total GLP-1 levels at fasting and 30 min were significantly higher in T2DM compared with pre-DM and NGT (27.18 +/- 11.56 pmol/L vs. 21.99 +/- 10.16 pmol/L vs. 16.24 +/- 7.79 pmol/L, p=0.001; and 50.22 +/- 18.03 pmol/L vs. 41.05 +/- 17.68 pmol/L vs. 31.44 +/- 22.59 pmol/L, p<0.001; respectively). Ethnicity was a significant determinant of AUC(GLP-1), with the Indians exhibiting higher GLP-1 responses than Chinese and Malays. Indians were the most insulin resistant, whereas Chinese were the most insulin sensitive. The GLP-1 levels were positively correlated with HOMA-IR and TyG but negatively correlated with HOMA-IS. This relationship was evident among Indians who exhibited augmented GLP-1 responses proportionately to their high insulin-resistant states. CONCLUSION: This is the first study that showed GLP-1 responses are augmented as IR states increase. Fasting and post-OGTT GLP-1 levels are raised in T2DM and pre-DM compared to that in NGT. This raises a possibility of an adaptive compensatory response that has not been reported before. Among the three ethnic groups, the Indians has the highest IR and GLP-1 levels supporting the notion of an adaptive compensatory secretion of GLP-1. CI - Copyright (c) 2022 Chong, Sukor, Robert, Ng and Kamaruddin. FAU - Chong, Shiau Chin AU - Chong SC AD - Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre (UKMMC), Kuala Lumpur, Malaysia. FAU - Sukor, Norlela AU - Sukor N AD - Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre (UKMMC), Kuala Lumpur, Malaysia. FAU - Robert, Sarah Anne AU - Robert SA AD - Department of Pharmacy, Universiti Kebangsaan Malaysia Medical Centre (UKMMC), Kuala Lumpur, Malaysia. FAU - Ng, Kim Fong AU - Ng KF AD - Department of Cardiology, Hospital Sultanah Aminah Johor Bahru, Johor, Malaysia. FAU - Kamaruddin, Nor Azmi AU - Kamaruddin NA AD - Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre (UKMMC), Kuala Lumpur, Malaysia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220909 PL - Switzerland TA - Front Endocrinol (Lausanne) JT - Frontiers in endocrinology JID - 101555782 RN - 0 (Blood Glucose) RN - 0 (Incretins) RN - 0 (Insulin) RN - 0 (Triglycerides) RN - 89750-14-1 (Glucagon-Like Peptide 1) SB - IM MH - Blood Glucose MH - *Diabetes Mellitus, Type 2 MH - Ethnicity MH - Fasting MH - Glucagon-Like Peptide 1 MH - Humans MH - Incretins MH - Insulin MH - *Insulin Resistance MH - *Prediabetic State MH - Triglycerides PMC - PMC9501699 OTO - NOTNLM OT - ethnicity OT - glucagon-like peptide-1 OT - glucose tolerance OT - incretin OT - insulin resistance OT - pre-diabetes OT - secretion OT - type 2 diabetes mellitus COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/09/27 06:00 MHDA- 2022/09/28 06:00 PMCR- 2022/01/01 CRDT- 2022/09/26 17:09 PHST- 2022/06/04 00:00 [received] PHST- 2022/08/22 00:00 [accepted] PHST- 2022/09/26 17:09 [entrez] PHST- 2022/09/27 06:00 [pubmed] PHST- 2022/09/28 06:00 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fendo.2022.961432 [doi] PST - epublish SO - Front Endocrinol (Lausanne). 2022 Sep 9;13:961432. doi: 10.3389/fendo.2022.961432. eCollection 2022.